+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biomarker Testing Services Market by Biomarker Type, Technology, Application, End User - Global Forecast to 2030- Product Image
Biomarker Testing Services Market by Biomarker Type, Technology, Application, End User - Global Forecast to 2030- Product Image
Sale

Biomarker Testing Services Market by Biomarker Type, Technology, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715912
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biomarker Testing Services Market grew from USD 1.03 billion in 2024 to USD 1.11 billion in 2025. It is expected to continue growing at a CAGR of 7.42%, reaching USD 1.58 billion by 2030.

Introduction to Biomarker Testing’s Strategic Imperative

Biomarker testing services lie at the intersection of cutting-edge science and clinical decision-making, serving as a cornerstone for personalized healthcare and drug development. As the molecular underpinnings of disease continue to be unraveled, biomarkers provide invaluable insights into disease progression, therapeutic response, and patient stratification. This convergence of biology, technology, and diagnostics is reshaping the healthcare paradigm, enabling more precise interventions and streamlined clinical workflows.

In an environment characterized by rapid technological innovation, shifting regulatory frameworks, and evolving payer landscapes, stakeholders across the healthcare ecosystem must navigate increasing complexity. From academic research laboratories to pharmaceutical development teams and clinical diagnostics providers, each participant seeks to harness biomarker data to drive better outcomes. This executive summary distills the transformative forces at play, offering a strategic lens through which to view market dynamics, segmentation intricacies, and actionable recommendations for industry leaders.

Emerging Forces Redefining the Biomarker Testing Ecosystem

The biomarker testing landscape is undergoing a fundamental transformation powered by technological breakthroughs, regulatory realignment, and the digitization of healthcare. Next-generation sequencing platforms have democratized access to comprehensive genomic profiling, while advanced immunoassays and mass spectrometry techniques offer unparalleled sensitivity in protein biomarker quantification. Simultaneously, artificial intelligence and machine learning are enhancing data interpretation, revealing complex molecular signatures that eluded traditional analytic approaches.

Regulators are responding to these innovations by updating approval pathways and reimbursement policies, signaling a shift toward value-based diagnostics. Health systems are increasingly integrating biomarker testing into routine clinical pathways, leveraging remote monitoring and telehealth solutions to extend diagnostic capabilities beyond centralized laboratories. These converging shifts are redefining value chains, fostering collaborative partnerships between diagnostic developers, research institutions, and healthcare providers. As a result, market participants are compelled to adopt agile strategies that anticipate technology adoption curves and regulatory milestones.

Navigating the Ripple Effects of 2025 Trade Policy Adjustments

The imposition of new United States tariffs in 2025 has introduced a significant layer of complexity to the biomarker testing supply chain. Tariff adjustments on imported reagents, consumables, and instrumentation have elevated input costs for laboratories and diagnostic developers. Equipment manufacturers are reassessing their procurement strategies, evaluating alternative sourcing from tariff-free trade partners or ramping up domestic production to mitigate cost pressures.

These cumulative impacts extend beyond direct pricing implications. Higher reagent costs have prompted some laboratories to optimize assay workflows, consolidating test panels and negotiating volume-based agreements with suppliers. Strategic alliances have emerged between reagent producers and diagnostic service providers to co-develop bundled solutions that absorb tariff shocks. Meanwhile, shifts in supplier geography have triggered logistical challenges, from extended lead times to heightened inventory requirements. Navigating this evolving landscape demands proactive risk management and supply chain resilience to uphold quality standards and maintain competitive pricing.

Deep Dive into Market Segmentation Dynamics

Segmentation analysis reveals nuanced growth pockets driven by biomarker type, technology, application, and end-user profiles. Within biomarker type, the cellular biomarker segment, anchored by flow cytometry and immunophenotyping techniques, demonstrates robust demand for cell sorting and multi-color assays to support immuno-oncology research. Genetic biomarkers chart distinct trajectories: DNA assays remain anchored by next-generation sequencing platforms and polymerase chain reaction methods, while RNA biomarker adoption accelerates through microarray and quantitative PCR modalities. Meanwhile, protein biomarkers retain their centrality in diagnostic workflows, with ELISA formats-both competitive and sandwich-continuing to address high-throughput screening needs alongside mass spectrometry and western blot analyses.

Technology segmentation underscores the evolving interplay between immunoassay, mass spectrometry, and molecular diagnostics. Immunoassays bridge classical and modern approaches through CLIA-certified platforms, ELISA variants, and radioimmunoassays, while molecular diagnostic advancements leverage microarray chips, high-throughput sequencing, and PCR refinements such as digital and quantitative PCR. Application segmentation highlights companion diagnostics in oncology and personalized medicine as high-growth vectors, complemented by disease diagnosis across cardiovascular, infectious disease, and oncology domains, and underpinned by drug development activities spanning clinical trials, early-stage discovery, and toxicology screening. End-user segmentation reflects diverse adoption patterns among clinical laboratories-both hospital-based and independent-hospitals across private and public systems, pharmaceutical entities from large-cap pharma to agile biotech, and research institutes in academic and government settings.

Uncovering Regional Drivers and Growth Patterns

Regional analysis uncovers distinct market drivers and maturation levels across the Americas, EMEA, and Asia-Pacific. In the Americas, strong healthcare infrastructure and progressive reimbursement frameworks fuel demand for advanced molecular assays and high-throughput platforms. Collaboration between academic medical centers and biopharma sponsors underpins robust companion diagnostic pipelines, particularly in oncology.

Europe, the Middle East, and Africa present a mosaic of regulatory environments and healthcare funding models. While Western Europe emphasizes harmonized regulatory standards and cost-effectiveness, emerging markets in Eastern Europe and the Middle East are characterized by increasing private investment in diagnostic capacity. Africa’s growth trajectory hinges on public-private partnerships to address infectious disease testing needs and build local manufacturing capabilities.

Asia-Pacific remains a dynamic growth arena, propelled by sizable patient populations, government-led precision medicine initiatives, and expansion of domestic diagnostic manufacturing. Countries such as China, Japan, and South Korea are intensifying R&D investments and regulatory reforms to accelerate market entry of novel biomarker tests, while Southeast Asian markets are rapidly adopting point-of-care solutions to broaden diagnostic access.

Competitive Landscape and Strategic Differentiators

Major players in the biomarker testing market are distinguished by their integrated solutions, strategic partnerships, and targeted innovation pipelines. Established diagnostics conglomerates leverage global distribution networks and comprehensive product portfolios to maintain market leadership across immunoassays, sequencing, and mass spectrometry platforms. Instrument vendors differentiate through modular designs and automation features that enhance laboratory efficiency and throughput.

Emerging biotech firms focus on niche biomarker panels and proprietary assay chemistries, forging collaborations with academic institutions to validate clinical utility and secure regulatory clearances. Contract research organizations and specialty laboratories are capitalizing on contract manufacturing and testing services, offering end-to-end capabilities from assay development through regulatory submission support. The competitive landscape is further shaped by technology alliances that integrate AI-driven analytics into diagnostic workflows, underscoring the importance of data-centric offerings in capturing future growth.

Strategic Pathways for Sustained Market Leadership

Industry leaders should pursue a multi-pronged strategy that balances innovation, operational excellence, and strategic alliances. Prioritizing modular platform design and automation can drive cost efficiencies and expedite time-to-market for new assays. Investment in advanced data analytics and AI capabilities will enhance assay development, quality control, and predictive maintenance, solidifying competitive advantage.

Collaboration with academic and clinical partners is essential to co-develop evidence-based biomarker tests and secure payer endorsements. Geographic diversification of manufacturing and supply chain networks will mitigate tariff-related risks and ensure business continuity. Leaders must also engage proactively with regulators and payers to shape favorable coverage policies, leveraging real-world evidence to demonstrate clinical and economic value. By adopting this integrated approach, companies can navigate market complexities and capitalize on high-growth segments.

Robust Methodology Underpinning Actionable Insights

This report synthesizes insights from an extensive research methodology combining secondary and primary data sources. Secondary research encompassed peer-reviewed journals, regulatory filings, company financial reports, and industry white papers to establish baseline market context. Primary research included structured interviews with key opinion leaders, diagnostics executives, clinical laboratory managers, and payers to capture real-world perspectives on technology adoption, reimbursement trends, and operational challenges.

Data triangulation methods ensured the consistency and credibility of findings, while rigorous quality assurance protocols validated analytical assumptions. Segmentation frameworks were constructed based on biomarker type, technology, application, and end-user criteria, aligning with standard industry classifications. Geographic coverage spanned the Americas, EMEA, and Asia-Pacific, with nuanced analysis of regional regulatory frameworks, healthcare infrastructure, and market access dynamics. All information was subjected to editorial and technical review to uphold the highest standards of accuracy and clarity.

Synthesis of Key Market Insights and Outlook

The evolving landscape of biomarker testing services presents unprecedented opportunities and challenges for stakeholders across the healthcare continuum. Technological innovation, dynamic regulatory environments, and shifting trade policies are collectively reshaping market structures and competitive dynamics. A granular understanding of segmentation nuances and regional drivers is critical for informed decision-making.

Industry participants that embrace modular technology platforms, strategic collaborations, and data-driven approaches will be best positioned to capture value in companion diagnostics, disease diagnosis, and drug development. Proactive engagement with regulators and payers, coupled with diversified supply chain strategies, will mitigate emerging risks and unlock new growth corridors. As the market continues to mature, the ability to translate complex biomarker data into actionable insights will define the next frontier of personalized medicine.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Biomarker Type
    • Cellular Biomarker
      • Flow Cytometry
        • Cell Sorting
        • Multi-Color
      • Immunophenotyping
    • Genetic Biomarker
      • Dna Biomarker
        • Ngs
        • Pcr
      • Rna Biomarker
        • Microarray
        • Qpcr
    • Protein Biomarker
      • Elisa
        • Competitive Elisa
        • Sandwich Elisa
      • Mass Spectrometry
      • Western Blot
  • Technology
    • Immunoassay
      • Clia
      • Elisa
        • Competitive
        • Sandwich
      • Ria
    • Mass Spectrometry
    • Molecular Diagnostics
      • Microarray
      • Ngs
      • Pcr
        • Digital Pcr
        • Qpcr
  • Application
    • Companion Diagnostics
      • Oncology
      • Personalized Medicine
    • Disease Diagnosis
      • Cardiovascular
      • Infectious Disease
      • Oncology
    • Drug Development
      • Clinical Trials
      • Discovery
      • Toxicology
  • End User
    • Clinical Laboratory
      • Hospital Lab
      • Independent Lab
    • Hospital
      • Private Hospital
      • Public Hospital
    • Pharmaceutical Company
      • Big Pharma
      • Biotech
    • Research Institute
      • Academic
      • Government
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics Incorporated
  • Eurofins Scientific SE
  • Charles River Laboratories International, Inc.
  • Bio-Rad Laboratories, Inc.
  • ICON plc
  • IQVIA Holdings, Inc.
  • SGS SA
  • WuXi AppTec Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biomarker Testing Services Market, by Biomarker Type
8.1. Introduction
8.2. Cellular Biomarker
8.2.1. Flow Cytometry
8.2.1.1. Cell Sorting
8.2.1.2. Multi-Color
8.2.2. Immunophenotyping
8.3. Genetic Biomarker
8.3.1. Dna Biomarker
8.3.1.1. Ngs
8.3.1.2. Pcr
8.3.2. Rna Biomarker
8.3.2.1. Microarray
8.3.2.2. Qpcr
8.4. Protein Biomarker
8.4.1. Elisa
8.4.1.1. Competitive Elisa
8.4.1.2. Sandwich Elisa
8.4.2. Mass Spectrometry
8.4.3. Western Blot
9. Biomarker Testing Services Market, by Technology
9.1. Introduction
9.2. Immunoassay
9.2.1. Clia
9.2.2. Elisa
9.2.2.1. Competitive
9.2.2.2. Sandwich
9.2.3. Ria
9.3. Mass Spectrometry
9.4. Molecular Diagnostics
9.4.1. Microarray
9.4.2. Ngs
9.4.3. Pcr
9.4.3.1. Digital Pcr
9.4.3.2. Qpcr
10. Biomarker Testing Services Market, by Application
10.1. Introduction
10.2. Companion Diagnostics
10.2.1. Oncology
10.2.2. Personalized Medicine
10.3. Disease Diagnosis
10.3.1. Cardiovascular
10.3.2. Infectious Disease
10.3.3. Oncology
10.4. Drug Development
10.4.1. Clinical Trials
10.4.2. Discovery
10.4.3. Toxicology
11. Biomarker Testing Services Market, by End User
11.1. Introduction
11.2. Clinical Laboratory
11.2.1. Hospital Lab
11.2.2. Independent Lab
11.3. Hospital
11.3.1. Private Hospital
11.3.2. Public Hospital
11.4. Pharmaceutical Company
11.4.1. Big Pharma
11.4.2. Biotech
11.5. Research Institute
11.5.1. Academic
11.5.2. Government
12. Americas Biomarker Testing Services Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biomarker Testing Services Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biomarker Testing Services Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Laboratory Corporation of America Holdings
15.3.3. Quest Diagnostics Incorporated
15.3.4. Eurofins Scientific SE
15.3.5. Charles River Laboratories International, Inc.
15.3.6. Bio-Rad Laboratories, Inc.
15.3.7. ICON plc
15.3.8. IQVIA Holdings, Inc.
15.3.9. SGS SA
15.3.10. WuXi AppTec Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOMARKER TESTING SERVICES MARKET MULTI-CURRENCY
FIGURE 2. BIOMARKER TESTING SERVICES MARKET MULTI-LANGUAGE
FIGURE 3. BIOMARKER TESTING SERVICES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOMARKER TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOMARKER TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOMARKER TESTING SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MULTI-COLOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY NGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY QPCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPETITIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY SANDWICH, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY RIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY NGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY QPCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL LAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY INDEPENDENT LAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOTECH, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES BIOMARKER TESTING SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 128. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 129. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 130. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 131. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 132. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 133. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 134. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 135. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 136. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 138. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 139. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 196. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 197. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 198. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOMARKER TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 240. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 258. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 261. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 262. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 263. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 264. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 265. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 266. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 267. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 268. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 269. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 271. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 272. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 273. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 274. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 276. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 277. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 278. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 280. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 281. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 282. GERMANY BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 283. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 284. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 285. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 286. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 287. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 288. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 289. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 290. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 291. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 293. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 294. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 295. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 296. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 297. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 298. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY DISEASE DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 299. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 300. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY CLINICAL LABORATORY, 2018-2030 (USD MILLION)
TABLE 302. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 303. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANY, 2018-2030 (USD MILLION)
TABLE 304. FRANCE BIOMARKER TESTING SERVICES MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 306. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY CELLULAR BIOMARKER, 2018-2030 (USD MILLION)
TABLE 307. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 308. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY GENETIC BIOMARKER, 2018-2030 (USD MILLION)
TABLE 309. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY DNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 310. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY RNA BIOMARKER, 2018-2030 (USD MILLION)
TABLE 311. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY PROTEIN BIOMARKER, 2018-2030 (USD MILLION)
TABLE 312. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY ELISA, 2018-2030 (USD MILLION)
TABLE 313. RUSSIA BIOMARKER TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 314. RUSS

Companies Mentioned

The companies profiled in this Biomarker Testing Services market report include:
  • Thermo Fisher Scientific Inc.
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics Incorporated
  • Eurofins Scientific SE
  • Charles River Laboratories International, Inc.
  • Bio-Rad Laboratories, Inc.
  • ICON plc
  • IQVIA Holdings, Inc.
  • SGS SA
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.11 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.58 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biomarker Testing Services - Global Strategic Business Report - Product Image

Biomarker Testing Services - Global Strategic Business Report

  • Report
  • 152 Pages
  • Global
From
Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Application (Oncology, Drug Discovery & Development), By Type, By End-use,By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Service (Biomarker Assay Development & Validation, Flow Cytometry), By Application (Oncology, Drug Discovery & Development), By Type, By End-use,By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cardiac Biomarkers Testing Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Metabolic Biomarker Testing Market Report 2025 - Product Image

Metabolic Biomarker Testing Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Diagnostic Biomarker Market

A diagnostic biomarker is a biological molecule or gene that is used to identify a particular disease or condition. It is used to diagnose, monitor, and predict the progression of a disease or condition. Diagnostic biomarkers are used to detect the presence of a disease or condition, to determine the severity of the disease or condition, and to monitor the effectiveness of treatments. Diagnostic biomarkers are used in a variety of medical fields, including oncology, neurology, cardiology, and infectious diseases. Diagnostic biomarkers are typically identified through a variety of methods, including genetic sequencing, proteomics, and metabolomics. These methods allow for the identification of biomarkers that are specific to a particular disease or condition. The diagnostic biomarker market is a rapidly growing field, with many companies developing and marketing diagnostic biomarkers. Companies in this market include Illumina, Thermo Fisher Scientific, Qiagen, Roche, and Agilent Technologies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.